Dr. Edward Pearson explores the latest advancement in anti-CD38 therapy: subcutaneous delivery of isatuximab via on-body injector. He reviews clinical evidence on efficacy, safety, and patient preference, and shares how he anticipates this innovation to impact clinic workflows, care teams, and the overall multiple myeloma patient experience.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Brook Cox, BSN, RN, OCN, an oncology nurse and infusion room supervisor, shares how subcutaneous administration of anti-CD38 therapy has transformed infusion center operations, improved patient flow, and created both opportunities and challenges for nursing teams caring for patients with multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson reviews pivotal clinical trial data supporting anti-CD38-based regimens and explores how clinicians can balance efficacy, tolerability, and quality of life when managing high-risk and transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Edward Pearson discusses the growing role of anti-CD38-based quadruplet therapy and key considerations influencing frontline therapy selection for patients with newly diagnosed, transplant-ineligible multiple myeloma.
This episode is part of the micro-series, Optimizing Care in Multiple Myeloma: Perspectives on Treatment and Delivery Innovation.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Take a closer look at DLL3 as an emerging biomarker and therapeutic target in EP‑NEC. Dr. Meredith Pelster discusses the biology behind DLL3 overexpression and the latest clinical data on DLL3‑directed therapies, including bispecific T‑cell engagers.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

With limited durable options available, new approaches are urgently needed in EP-NEC. Dr. Meredith Pelster highlights emerging therapies, including immunotherapy‑based strategies and early clinical trial data shaping future treatment directions.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Explore the current EP‑NEC treatment landscape, from first‑line platinum‑based therapy and etoposide to second‑line challenges. Dr. Meredith Pelster reviews guideline‑recommended options, sequencing considerations, and why clinical trials are essential in this aggressive disease.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

Dr. Meredith Pelster introduces extrapulmonary neuroendocrine carcinoma (EP‑NEC), outlining how patients present and what distinguishes this rare disease. Learn the key elements of diagnostic workup, including pathology, imaging, and features that differentiate EP‑NEC from other neuroendocrine tumors.
This episode is part of the micro-series, EP-NEC Explained: Diagnosis to Emerging Therapies.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In the final episode of this four-part series, Dr. Mohit Narang looks ahead to emerging innovations in multiple myeloma. Learn about new therapeutic targets, MRD testing, sequencing strategies, and personalized approaches that aim to optimize outcomes and bring us closer to functional cures.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.

In part three of four, Dr. Mohit Narang explores how bispecific antibodies and other advanced treatments are being implemented in real-world community oncology practices. Discover the operational challenges, safety considerations, and strategies that enable community oncology centers to expand access to these transformative therapies for the broader patient population.
This episode is part of the Micro-Series, Multiple Myeloma in 2025: Transformative Progress, the Latest Innovation, and Future Opportunities.
Developed and produced by Ontada Learn. The content is intended for educational purposes and reflects current research and expert opinion as of the release date.